CoChat

Milnacipran versus other antidepressive agents for depression

Open access
Nakagawa, Atsuo, Watanabe, Norio, Omori, Ichiro M, Barbui, Corrado, Cipriani, Andrea, McGuire, Hugh, Churchill, Rachel, Furukawa, Toshi A · 2009 · Cochrane Database of Systematic Reviews
Cited by 56

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Although pharmacological and psychological interventions are both effective for major depression, antidepressant drugs are frequently used as first-line treatment in primary and secondary care settings. Milnacipran, a dual serotonin-norepinephrine reuptake inhibitor (SNRI), is one of the antidepressant drugs that clinicians use for routine depression care. OBJECTIVES: To assess the evidence for the efficacy, acceptability and tolerability of milnacipran in comparison with tricyclic antidepressants (TCAs), heterocyclics, SSRIs and other newer antidepressive agents in the acute-phase treatment of major depression. SEARCH STRATEGY: The Cochrane Collaboration Depression, Anxiety & Neurosis review group Controlled Trials Register (CCDANCTR-Studies and CCDANCTR-References) were electronically searched in August 2008. References of relevant trials and other reviews were also checked. Trial databases of the drug-approving agencies and ongoing clinical trial registers for all published and unpublished trials were hand-searched in 2007. All relevant authors were contacted for supplemental data. No language restriction was applied. SELECTION CRITERIA: Randomised controlled trials comparing milnacipran with any other active antidepressive agents (including non-conventional agents such as herbal products like hypericum) as monotherapy in the acute phase of major depression were selected. DATA COLLECTION AND ANALYSIS: Two reviewers independently checked eligibility, assessed methodological quality and extracted data from the eligible trials using a standardised data extraction form. The number of participants who responded to treatment or those who achieved remission were calculated on an intention-to-treat basis. Random-effects meta-analyses were conducted, combining data from the included trials. MAIN RESULTS: A total of 16 randomised controlled trials (n=2277) were included in the meta-analysis.Despite the size of this sample, the pooled 95% confidence intervals were rather wide and there were no statistically significant differences in efficacy, acceptability and tolerability when comparing milnacipran with other antidepressive agents. However, compared with TCAs, patients taking milnacipran were associated with fewer dropouts due to adverse events (OR 0.55; 95%CI 0.35 to 0.85). There was also some weak evidence to suggest that patients taking milnacipran experienced fewer adverse events of sleepiness/ drowsiness, dry mouth or constipation compared with TCAs. AUTHORS' CONCLUSIONS: Currently, there is inadequate evidence to conclude whether milnacipran is superior, inferior or the same as other antidepressive agents in terms of efficacy, acceptability and tolerability in the acute phase treatment of major depression. However, there is some evidence in favour of milnacipran over TCAs in terms of dropouts due to adverse events (acceptability) and the rates of experiencing adverse events (tolerability). Information about other clinically meaningful outcomes such as cost-effectiveness and social functioning, including the ability to return to work, is lacking. Further study is needed to answer whether milnacipran would be the better choice of antidepressant for acute major depression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd006529.pub2

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 106

  1. Ansseau, 1989, Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients, Psychopharmacology, 98, 163, 10.1007/BF00444686 · DOI
  2. Frenckell, 1990, Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies, International Clinical Psychopharmacology, 5, 49, 10.1097/00004850-199001000-00005 · DOI
  3. Ansseau, 1989, Controlled comparison of milnacipran (F2207) 200 mg and amitriptyline in endogenous depressive inpatients, Human Psychopharmacology, 4, 221, 10.1002/hup.470040308 · DOI
  4. Ansseau, 1990, Controlled comparison of milnacipran (F2207) 200 mg and amitriptyline in endogenous depressive inpatients, Therapie, 45, 292
  5. Ansseau, 1991, Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine, European Neuropsychopharmacology, 1, 113, 10.1016/0924-977X(91)90712-4 · DOI
  6. Ansseau, 1994, Controlled comparison of milnacipran and fluoxetine in major depression, Psychopharmacology, 114, 131, 10.1007/BF02245454 · DOI
  7. Clerc, 2001, Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: A comparison with fluvoxamine, International Clinical Psychopharmacology, 16, 145, 10.1097/00004850-200105000-00003 · DOI
  8. Endo, 1995, Clinical Evaluation of Milnacipran Hydrochloride, a New Antidepressant for Depression and Depressive State Phase III Clinical Trial with Mianserin Hydrochloride as a Control Drug, Rinsho Hyoka, 23, 39
  9. Guelfi, 1998, A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients, International Clinical Psychopharmacology, 13, 121, 10.1097/00004850-199805000-00005 · DOI · Paper page
  10. Lee, 2002, A comparison of the efficacy and safety between milnacipran and fluoxetine in the treatment of patients with depression, International Journal of Neuropsychopharmacology, 5, 205
  11. Lee, 2005, Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression, Current Medical Research & Opinion, 21, 1369, 10.1185/030079905X59166 · DOI
  12. Leinonen, 1997, Long-term efficacy and safety of milnacipran compared to clomipramine inpatients with major depression, Acta Psychiatrica Scandinavica, 96, 497, 10.1111/j.1600-0447.1997.tb09953.x · DOI
  13. Lopez-Ibor, 2004, A comparative study of milnacipran and imipramine in the treatment of major depressive disorder, Current Medical Research and Opinion, 20, 855, 10.1185/030079904125003719 · DOI
  14. Sechter, 2004, A comparative study of milnacipran and paroxetine in outpatients with major depression, Journal of Affective Disorders, 83, 233, 10.1016/j.jad.2004.07.002 · DOI
  15. Sechter, 2000, Psychomotor retardation is a predictive factor of milnacipran response, International Journal of Neuropsychopharmacology, 3, 190
  16. Vandel, 2004, Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine, Human Psychopharmacology, 19, 585, 10.1002/hup.644 · DOI
  17. Shinkai, 2004, Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment, Journal of Clinical Psychopharmacology, 24, 11, 10.1097/01.jcp.0000104904.75206.19 · doi:10.1097/01.jcp.0000104904.75206.19
  18. Tignol, 1998, Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode, Acta Psychiatrica Scandinavica, 97, 157, 10.1111/j.1600-0447.1998.tb09980.x · DOI · Paper page
  19. Amerongen, 2002, A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression, Journal of Affective Disorders, 72, 21, 10.1016/S0165-0327(01)00422-0 · DOI
  20. Matsubara R Onodera I Ito K Okada F Asano Y A double-blind comparison of milnacipran and imipramine in depressive patients XXth Collegium Internationale Neuro psychopharmacologicum, Melbourne, Australia 1996 · doi:10.1016/0924-977x(96)87523-7
  21. Yamashita, 1995, Clinical evaluation of milnacipran hydrochloride (tn-912) on depression and depressive states -phase iii clinical trial with imipramine hydrochloride as a control drug, Rinsyoiyaku, 11, 819
  22. Yang, 2003, Milnacipran versus Sertraline in Major Depressive Disorder: A Double-Blind Randomized Comparative Study on the Treatment Effect and cbeta-Adrenergic Receptor Responsiveness, Korean Journal of Psychopharmacology, 14, 387
  23. Baek, 2002, The Effect of Antidepressant Treatment on Beta-Adrenergic Receptor Responsiveness in Patients with Major Depression, Korean Journal of Psychopharmacology, 13, 154
  24. Baek, 2002, The effect of antidepressant treatment on beta-adrenergic receptor responsiveness in patients with major depression, International Journal of Neuropsychopharmacology, 5, 148
  25. Dardennes, 2000, Economic assessment of a maintenance treatment strategy in prevention of recurrent depressive disorder, Value in Health, 3, 40, 10.1046/j.1524-4733.2000.31005.x · DOI
  26. Lafuma, 1999, Clinico-economic assessment of milnacipran in the prevention of depressive episodes, Encephale, 25, 401
  27. Rouillon, 2000, Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life, Journal of Affective Disorders, 58, 171, 10.1016/S0165-0327(99)00109-3 · DOI
  28. Kanemoto, 2004, Controlled comparison of two different doses of milnacipran in major depressive outpatients, International Clinical Psychopharmacology, 19, 343, 10.1097/00004850-200411000-00005 · doi:10.1097/00004850-200411000-00005
  29. Lee, 2004, The Efficacy and Safety of Milnacipran in Patients with Major Depression: A comparison with Fluoxetine, Journal of the Korean Neuropsychiatric Association, 43, 415
  30. Macher, 1989, Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders, Neuropsychobiology, 22, 77, 10.1159/000118596 · DOI
  31. Shingo, 2007, Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients, Psychiatry and Clinical Neurosciences, 61, 421, 10.1111/j.1440-1819.2007.01679.x · DOI
  32. Onodera, 1992, Double-blind controlled comparison of two doses of milnacipran in depressive patients, Clinical Neuropharmacology, 15, 418, 10.1097/00002826-199202001-00812 · doi:10.1097/00002826-199202001-00812
  33. Yoshimura, 2007, Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients, Progress in Neuropsychopharmacology and Biological Psychiatry, 31, 1034–7, 10.1016/j.pnpbp.2007.03.001 · DOI · Paper page
  34. Anderson, 2000 Mar, Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines.British Association for Psychopharmacology, Journal of Psychopharmacology, 14, 3, 10.1177/026988110001400101 · DOI · Paper page
  35. American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders (DSM-III)
  36. American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)
  37. American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
  38. American Psychiatric Association, 2000 Apr, Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association, American Journal of Psychiatry, 157, 1
  39. Appleton, 2006, Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials, American Journal of Clinical Nutrition, 84, 1308, 10.1093/ajcn/84.6.1308 · DOI · Paper page
  40. Barbui, 2004 Apr, "Wish bias" in antidepressant drug trials?, Journal of Clinical Psychopharmacology, 24, 126, 10.1097/01.jcp.0000115665.45074.0d · DOI · Paper page
  41. Barbui, 2007, Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence, Cochrane Database of Systematic Reviews
  42. Bhandari, Association between industry funding and statistically significant pro-industry findings in medical and surgical randomised trials, Canadian Medical Association Journal, 170, 477
  43. Briley, 1996, Preclinical pharmacology of milnacipran, International Clinical Psychopharmacology, 11, 9, 10.1097/00004850-199609004-00002 · DOI · Paper page
  44. Buchkowsky, 2004 Apr, Industry sponsorship and authorship of clinical trials over 20 years, Annals of Pharmacotherapy, 38, 579, 10.1345/aph.1D267 · DOI · Paper page
  45. Cipriani, Fluoxetine versus other types of pharmacotherapy for depression, Cochrane Database of Systematic Reviews
  46. Cipriani, 2007, Paroxetine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews
  47. Cipriani, 2007, Venlafaxine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews
  48. Cipriani, 2009, Sertraline versus other antidepressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006117.pub2 · DOI · Paper page
  49. Ciuna, 2004 Nov, Are we going to increase the use of antidepressants up to that of benzodiazepines?, European Journal of Clinical Pharmacology, 60, 629, 10.1007/s00228-004-0810-8 · DOI
  50. Cowen, 2005, Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression, Current Medical Research and Opinion, 21, 345
  51. Coyne, 1994 Jul, Prevalence, nature, and comorbidity of depressive disorders in primary care, General Hospital Psychiatry, 16, 267, 10.1016/0163-8343(94)90006-X · DOI · Paper page
  52. Ellis, 2004 Jun, Australian and New Zealand clinical practice guidelines for the treatment of depression, Australian and New Zealand Journal of Psychiatry, 38, 389, 10.1111/j.1440-1614.2004.01377.x · DOI
  53. Frampton, 2007, Duloxetine : a review of its use in the treatment of major depressive disorder, CNS Drugs, 21, 581, 10.2165/00023210-200721070-00004 · DOI
  54. Furukawa, Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review, BMJ, 325, 991, 10.1136/bmj.325.7371.991 · DOI · Paper page
  55. Geddes, 2000, SSRIs versus other antidepressants for depressive disorder, Cochrane Database of Systematic Reviews
  56. Guaiana, 2005 Jun, Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000, Journal of Clinical Psychiatry, 66, 750, 10.4088/JCP.v66n0612 · DOI · Paper page
  57. Guaiana, 2007, Amitriptyline versus other types of pharmacotherapy for depression, Cochrane Database of Systematic Reviews
  58. Guelfi, 1998 May, A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients, International Clinical Psychopharmacology, 13, 121, 10.1097/00004850-199805000-00005 · DOI · Paper page
  59. Guy, 1970, Manual for the ECDEU Assessment Battery.2. Chevy Chase, MD: National Institute ofMental Health, 1970.
  60. Hamilton, 1960, A rating scale for depression, Journal of Neurology, Neurosurgery and Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  61. Hansen, Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder, Annals of Internal Medicine, 143, 415, 10.7326/0003-4819-143-6-200509200-00006 · DOI · Paper page
  62. Heres, 2006, Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics, American Journal of Psychiatry, 163, 185, 10.1176/appi.ajp.163.2.185 · DOI · Paper page
  63. Higgins, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  64. Higgins, May 2005, Cochrane Handbook for Systematic Reviews of Interventions 4.2.5
  65. Higgins, 2008, Section 8. Assessing risk of bias in included studies, 10.1002/9780470712184.ch8 · DOI · Paper page
  66. Imperadore, 2007, Citalopram versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006534 · DOI
  67. Ioannidis, 2006, Indirect comparisons: the mesh and mess of clinical trials, Lancet, 368, 1470, 10.1016/S0140-6736(06)69615-3 · DOI
  68. Ito, 2002, A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine, Psychiatry Research, 111, 235, 10.1016/S0165-1781(02)00141-5 · DOI
  69. Kessler, National Comorbidity Survey Replication, JAMA, 289, 3095, 10.1001/jama.289.23.3095 · DOI · Paper page
  70. Khan, 2003 Mar, Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports, Neuropsychopharmacology, 28, 552, 10.1038/sj.npp.1300059 · DOI · Paper page
  71. Kupfer, 2002, Placebo in clinical trials for depression: complexity and necessity, JAMA, 287, 1853, 10.1001/jama.287.14.1853 · DOI
  72. Lecrubier, 1996 Sep, Clinical efficacy of milnacipran: placebo-controlled trials, International Clinical Psychopharmacology, 11, 29, 10.1097/00004850-199609004-00004 · DOI · Paper page
  73. Linde, 2008, St John's wort for major depression, Cochrane Database of Systematic Reviews
  74. Lopez-Ibor, 1996 Sep, Milnacipran and selective serotonin reuptake inhibitors in major depression, International Clinical Psychopharmacology, 11, 41, 10.1097/00004850-199609004-00006 · DOI · Paper page
  75. Lu, 2004, Combination of direct and indirect evidence in mixed treatment comparison, Statistics in Medicine, 23, 3105, 10.1002/sim.1875 · DOI · Paper page
  76. Lu, 2006, Assessing evidence consistency in mixed treatment comparisons, Journal of the American Statistical Association, 101, 447, 10.1198/016214505000001302 · DOI · Paper page
  77. Luborsky, 1962, Clinician's judgments of mental health, Archives of General Psychiatry, 7, 407, 10.1001/archpsyc.1962.01720060019002 · DOI · Paper page
  78. Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
  79. Montgomery, 2004 Dec, An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia, Controlled Clinical Trials, 25, 598, 10.1016/j.cct.2004.09.002 · DOI
  80. Moret, 1985, Biochemical profile of milnacipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug, Neuropharmacology, 24, 1211, 10.1016/0028-3908(85)90157-1 · DOI · Paper page
  81. NICE, 2007, Depression: management of depression in primary and secondary care (amended)
  82. Nose, 2007, Duloxetine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006533 · DOI
  83. Okamura, 2006, Remission rates with milnacipran 100mg/day and 150 mg/day in the long-term treatment of major depression, Clinical Drug Investigation, 26, 135, 10.2165/00044011-200626030-00003 · DOI
  84. Omori, 2006, Fluvoxamine versus other anti-depressive agents for depression. (Protocol), Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006114 · DOI
  85. Papakostas, 2007, A meta-analysis of clinical trials comparing milnacipran, a serotonin-norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder, European Neuropsychopharmacology, 17, 32, 10.1016/j.euroneuro.2006.05.001 · DOI
  86. Procyshyn, 2004 Sep, Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine, Canadian Journal of Psychiatry, 49, 601, 10.1177/070674370404900905 · DOI · Paper page
  87. Psaty, 2003, Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis, JAMA, 289, 2533, 10.1001/jama.289.19.2534 · DOI · Paper page
  88. Puech, 1997 Mar, Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability, International Clinical Psychopharmacology, 12, 99, 10.1097/00004850-199703000-00005 · DOI · Paper page
  89. Puozzo, 1996 Sep, Pharmacokinetics of milnacipran in comparison with other antidepressants, International Clinical Psychopharmacology, 11, 15, 10.1097/00004850-199609004-00003 · DOI
  90. Puozzo, 2005, Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in antidepressant metabolism, Clinical Pharmacokinetics, 44, 977, 10.2165/00003088-200544090-00007 · DOI
  91. Santaguida, 2005, Challenges in systematic reviews that evaluate drug efficacy or effectiveness, Annals of Internal Medicine, 142, 1066, 10.7326/0003-4819-142-12_Part_2-200506211-00006 · DOI
  92. Sawada, 2001, Pharmacokinetics and drug interactions of antidepressive agents, Nippon Rinsho, 59, 1539
  93. Sechter, 2004 Dec, A comparative study of milnacipran and paroxetine in outpatients with major depression, Journal of Affective Disorders, 83, 233, 10.1016/j.jad.2004.07.002 · DOI
  94. Smith, 2002 May, Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis, British Journal of Psychiatry, 180, 396, 10.1192/bjp.180.5.396 · DOI · Paper page
  95. Spencer, 1998 Sep, Milnacipran. A review of its use in depression, Drugs, 56, 405, 10.2165/00003495-199856030-00010 · DOI
  96. Steen, 1997 Sep, A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder, International Clinical Psychopharmacology, 12, 269, 10.1097/00004850-199709000-00004 · doi:10.1097/00004850-199709000-00004
  97. Thase, 2001, Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors, British Journal of Psychiatry, 178, 234, 10.1192/bjp.178.3.234 · DOI · Paper page
  98. Ware, 1993, SF-36 Health Survey Manual and Interpretation Guide
  99. Watanabe, 2006, Mirtazapine versus other anti-depressive agents for depression (Protocol)., Cochrane Database of Systematic Reviews
  100. World Health Organization, 1978, The Ninth Revision of the International Classification of Disease and Related Health Problems (ICD-9)
  101. World Health Organization, 1992, The Tenth Revision of the International Classification of Disease and Related Health Problems (ICD-10)
  102. World Health Organization, 2004, The Global Burden of Disease 2004 Update
  103. Williams, A systematic review of newer pharmacotherapies for depression in adults: evidence report summary, Annals of Internal Medicine, 132, 743, 10.7326/0003-4819-132-9-200005020-00011 · DOI · Paper page
  104. Williams, 2001, Standardizing the Hamilton Depression Rating Scale: past, present, and future, European Archives of Psychiatry and Clinical Neuroscience, 251, II16
  105. Wing, 1994, Measuring mental health outcomes: a perspective from the Royal College of Psychiatrists. Outcomes into Clinical Practice
  106. Yoshida, 2002, Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26, 383, 10.1016/S0278-5846(01)00287-1 · DOI · Paper page

Cited by

See all 56

Metadata

Authors
Nakagawa, A., Watanabe, N., Omori, I. M., Barbui, C., Cipriani, A., McGuire, H., Churchill, R., & Furukawa, T. A.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2009-07-08
Volume
2014
Issue
12
Pages
CD006529-CD006529
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1516838546
Cited by
56
References
26
FWCI
5.34
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Milnacipran versus other antidepressive agents for depression. https://app.cochat.ai/papers/10.1002/14651858.cd006529.pub2
The paper
Nakagawa, A., Watanabe, N., Omori, I. M., Barbui, C., Cipriani, A., McGuire, H., Churchill, R., & Furukawa, T. A. (2009). Milnacipran versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd006529.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.